DEP domain containing protein 1B (DEPDC1B) is overexpressed in a variety of malignant tissues and cells. As an oncoprotein, it participates in the occurrence and development of many kinds of cancers and regulates different malignant biological forms, including promoting tumor cell invasion, migration, proliferation and inhibiting apoptosis, which is closely related to the function of DEP, Rho GAP and other domains. This paper mainly combines the domain composition of oncoprotein DEPDC1B to explore the relationship between oncoprotein DEPDC1B and the occurrence, development and treatment of cancer, in order to provide a reference basis for further study of the mechanism of DEPDC1B in cancer and potential anticancer therapy.

1.Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.

2.Chang L, Ruiz P, Ito T, et al. Targeting pan-essential genes in cancer: challenges and opportunities[J]. Cancer Cell, 2021, 39(4): 466-479. DOI: 10.1016/j.ccell.2020.12.008.

3.Sokol S. A role for Wnts in morpho-genesis and tissue polarity[J]. Nat Cell Biol, 2000, 2(7): E124-125. DOI: 10.1038/35017136.

4.Ballon DR, Flanary PL, Gladue DP, et al. DEP-domain-mediated regulation of GPCR signaling responses [J]. Cell, 2006, 126(6): 1079-1093. DOI: 10.1016/j.cell.2006. 07.030.

5.Consonni SV, Maurice MM, Bos JL. DEP domains: structurally similar but functionally different[J]. Nat Rev Mol Cell Biol, 2014, 15(5): 357-362. DOI: 10.1038/nrm 3791.

6.Mistry J, Chuguransky S, Williams L, et al. Pfam: The protein families database in 2021[J]. Nucleic Acids Res, 2021, 49(D1): D412-D419. DOI: 10.1093/nar/gkaa913.

7.Chen SH, Hamm HE. DEP domains: more than just membrane anchors[J]. Dev Cell, 2006, 11(4): 436-438. DOI: 10.1016/j.devcel.2006.09.011.

8.Pan WJ, Pang SZ, Huang T, et al. Characterization of function of three domains in dishevelled-1: DEP domain is responsible fair membrane translocation of dishevelled-1[J]. Cell Res, 2004, 14(4): 324-330. DOI: 10.1038/sj.cr. 7290232.

9.Gong Z, Chu H, Chen J, et al. DEPDC1 upregulation promotes cell proliferation and predicts poor prognosis in patients with gastric cancer[J]. Cancer Biomark, 2021, 30(3): 299-307. DOI: 10.3233/CBM-201760.

10.Qu D, Cui F, Lu D, et al. DEP domain containing 1 predicts prognosis of hepatocellular carcinoma patients and regulates tumor proliferation and metastasis[J]. Cancer Sci, 2019, 110(1): 157-165. DOI: 10.1111/cas.13867.

11.Wang W, Li A, Han X, et al. DEPDC1 up‐regulates RAS expression to inhibit autophagy in lung adenocarcinoma cells[J]. J Cell Mol Med, 2020, 24(22): 13303-13313. DOI: 10.1111/jcmm.15947.

12.Wang Q, Li A, Jin J, et al. Targeted interfering DEP domain containing 1 protein induces apoptosis in A549 lung adenocarcinoma cells through the NF-kappaB signaling pathway[J]. Onco Targets Ther, 2017, 10: 4443-4454. DOI: 10.2147/OTT.S142244.

13.Caron A, Briscoe DM, Richard D, et al. DEPTOR at the nexus of cancer, metabolism, and immunity[J]. Physiol Rev, 2018, 98(3): 1765-1803. DOI: 10.1152/physrev.00064. 2017.

14.Ravala SK, Hopkins JB, Plescia CB, et al. The first DEP domain of the RhoGEF P-Rex1 autoinhibits activity and contributes to membrane binding[J]. J Biol Chem, 2020, 295(36): 12635-12647. DOI: 10.1074/jbc.RA120.014534.

15.Paclíková P, Bernatík O, Radaszkiewicz TW, et al. The N-terminal part of the dishevelled dep domain is required for Wnt/β-catenin signaling in mammalian cells[J]. Mol Cell Biol, 2017, 37(18): e00145-217. DOI: 10.1128/MCB.00145-17.

16.Tcherkezian J, Lamarche-Vane N. Current knowledge of the large RhoGAP family of proteins[J]. Biol Cell, 2007, 99(2): 67-86. DOI: 10.1042/BC20060086.

17.Hodge RG, Schaefer A, Howard SV, et al. RAS and RHO family GTPase mutations in cancer: twin sons of different mothers?[J]. Crit Rev Biochem Mol Biol, 2020, 55(4): 386-407. DOI: 10.1080/10409238.2020.1810622.

18.Warner H, Wilson BJ, Caswell PT. Control of adhesion and protrusion in cell migration by Rho GTPases[J]. Curr Opin Cell Biol, 2019, 56: 64-70. DOI: 10.1016/j.ceb.2018. 09.003.

19.Narumiya S, Thumkeo D. Rho signaling research: history, current status and future directions[J]. FEBS Lett, 2018, 592(11): 1763-1776. DOI: 10.1002/1873-3468.13087.

20.Su L, Agati JM, Parsons SJ. p190RhoGAP is cell cycle regulated and affects cytokinesis[J]. J Cell Biol, 2003, 163(3): 571-582. DOI: 10.1083/jcb.200308007.

21.Yang H, Hong D, Cho SY, et al. RhoGAP domain-containing fusions and PPAPDC1A fusions are recurrent and prognostic in diffuse gastric cancer[J]. Nat Commun, 2018, 9(1): 4439. DOI: 10.1038/s41467-018-06747-4.

22.Tolias KF, Duman JG, Um K. Control of synapse development and plasticity by Rho GTPase regulatory proteins[J]. Prog Neurobiol, 2011, 94(2): 133-148. DOI: 10.1016/j.pneurobio.2011.04.011.

23.Su YF, Liang CY, Huang CY, et al. A putative novel protein, DEPDC1B, is overexpressed in oral cancer patients, and enhanced anchorage-independent growth in oral cancer cells that is mediated by Rac1 and ERK[J]. J Biomed Sci, 2014, 21(1): 67. DOI: 10.1186/s12929-014-0067-1.

24.Figeac N, Pruller J, Hofer I, et al. DEPDC1B is a key regulator of myoblast proliferation in mouse and man[J]. Cell Prolif, 2020, 53(1): e12717. DOI: 10.1111/cpr.12717.

25.Johannsdottir HK, Jonsson G, Johannesdottir G, et al. Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors[J]. Int J Cancer, 2006, 119(5): 1052-1060. DOI: 10.1002/ijc.21934.

26.Boudreau HE, Broustas CG, Gokhale PC. Expression of BRCC3, a novel cell cycle regulated molecule, is associated with increased phospho-ERK and cell proliferation[J]. Int J Mol Med, 2007, 19(1): 29-39. DOI: 10.3892/ijmm.19.1.29.

27.Marchesi S, Montani F, Deflorian G, et al. DEPDC1B coordinates de-adhesion events and cell-cycle progression at mitosis[J]. Dev Cell, 2014, 31(4): 420-433. DOI: 10.1016/j.devcel.2014.09.009.

28.Yang Y, Liu L, Cai J, et al. DEPDC1B enhances migration and invasion of non-small cell lung cancer cells via activating Wnt/β-catenin signaling[J]. Biochem Biophys Res Commun, 2014, 450(1): 899-905. DOI: 10.1016/j.bbrc.2014.06.076.

29.Bai S, Chen T, Du T, et al. High levels of DEPDC1B predict shorter biochemical recurrence-free survival of patients with prostate cancer[J]. Oncol Lett, 2017, 14(6): 6801-6808. DOI: 10.3892/ol.2017.7027.

30.Zhang S, Shi W, Hu W, et al. DEP Domain-Containing Protein 1B (DEPDC1B) promotes migration and invasion in pancreatic cancer through the Rac1/PAK1-LIMK1-cofilin1 signaling pathway[J]. Onco Targets Ther, 2020, 13: 1481-1496. DOI: 10.2147/ott.s229055.

31.Liu X, Li T, Huang X, et al. DEPDC1B promotes migration and invasion in pancreatic ductal adenocarcinoma by activating the Akt/GSK3β/Snail pathway[J]. Oncol Lett, 2020, 20(5): 146. DOI: 10.3892/ol.2020.12009.

32.Pollino S, Benassi MS, Pazzaglia L, et al. Prognostic role of XTP1/DEPDC1B and SDP35/DEPDC1A in high grade soft-tissue sarcomas[J]. Histol Histopathol, 2018, 33(6): 597-608. DOI: 10.14670/HH-11-959.

33.Lai CH, Xu K, Zhou J, et al. DEPDC1B is a tumor promotor in development of bladder cancer through targeting SHC1[J]. Cell Death Dis, 2020, 11(11): 986. DOI: 10.1038/s41419-020-03190-6.

34.Sun Y, Zhang Z. In Silico Identification of crucial genes and specific pathways in hepatocellular cancer[J]. Genet Test Mol Biomarkers, 2020, 24(5): 296-308. DOI: 10.1089/gtmb. 2019.0242.

35.Dang XW, Pan Q, Lin ZH, et al. Overexpressed DEPDC1B contributes to the progression of hepatocellular carcinoma by CDK1[J]. Aging (Albany NY), 2021, 13(16): 20094-20115. DOI: 10.18632/aging.203016.

36.Wang L, Tang L, Xu R, et al. DEPDC1B regulates the progression of human chordoma through UBE2T-mediated ubiquitination of BIRC5[J]. Cell Death Dis, 2021, 12(8): 753. DOI: 10.1038/s41419-021-04026-7.

37.Chen X, Guo ZQ, Cao D, et al. Knockdown of DEPDC1B inhibits the development of glioblastoma[J]. Cancer Cell Int, 2020, 20: 310. DOI: 10.1186/s12935-020-01404-7.

38.Hu F, Fong KO, Cheung MPL, et al. DEPDC1B promotes melanoma angiogenesis and metastasis through sequestration of ubiquitin ligase CDC16 to stabilize secreted SCUBE3[J]. Adv Sci (Weinh), 2022, 9(10): e2105226. DOI: 10.1002/advs.202105226.

39.Xu Y, Sun W, Zheng B, et al. DEPDC1B knockdown inhibits the development of malignant melanoma through suppressing cell proliferation and inducing cell apoptosis[J]. Exp Cell Res, 2019, 379(1): 48-54. DOI: 10.1016/j.yexcr.2019.03.021.

40.Ahuja P, Singh K. In silico approach for SAR analysis of the predicted model of DEPDC1B: a novel target for oral cancer[J]. Adv Bioinformatics, 2016, 2016: 3136024. DOI: 10.1155/2016/3136024.

41.Li Z, Wang Q, Peng S, et al. The metastatic promoter DEPDC1B induces epithelial-mesenchymal transition and promotes prostate cancer cell proliferation via Rac1-PAK1 signaling[J]. Clin Transl Med, 2020, 10(6): e191. DOI: 10.1002/ctm2.191.

42.Gao D, Zhang X, Liu B, et al. Screening circular RNA related to chemotherapeutic resistance in breast cancer[J]. Epigenomics, 2017, 9(9): 1175-1188. DOI: 10.2217/epi-2017-0055.

43.Mehta M, Griffith J, Panneerselvam J, et al. Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage[J]. Int J Radiat Biol, 2021, 97(8): 1109-1120. DOI: 10.1080/09553002.2020.1730012.

44.Guo C, Wu Z, Lin W, et al. Suramin targets the conserved ligand-binding pocket of human raf1 kinase inhibitory protein[J].  Molecules, 2021, 26(4): 1151. DOI: 10.3390/molecules26041151.

45.Sanclemente M, Nieto P, Garcia-Alonso S, et al. RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression[J]. Cancer Cell, 2021, 39(3): 294-296. DOI: 10.1016/j.ccell.2021.01.008.

46.Niu N, Qin Y, Fridley BL, et al. Radiation pharmacoge nomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines[J]. Genome Res, 2010, 20(11): 1482-1492. DOI: 10.1101/gr.107672.110.